Related Experiment Video

Updated: Jun 4, 2026

A Recovery Cardiopulmonary Bypass Model Without Transfusion or Inotropic Agents in Rats
09:54

A Recovery Cardiopulmonary Bypass Model Without Transfusion or Inotropic Agents in Rats

Published on: March 23, 2018

Detrimental effect of cardiopulmonary bypass (CPB) on malignant disease

Ahmad K Darwazah1, Saleh Shehata

  • 1Department of Cardiac Surgery, Makassed Hospital, Jerusalem, Israel. darwaz30@hotmail.com

Journal of Cardiothoracic Surgery
|February 8, 2011
PubMed

Insights

Treating patients with both coronary artery disease and malignancy is challenging. Off-pump myocardial revascularization is a safe surgical option for these complex cases, whether performed combined or staged.

Area of Science:

  • Cardiovascular Surgery
  • Surgical Oncology
  • Oncologic Emergencies

Background:

  • Patients with concurrent coronary artery disease and malignancy present complex treatment challenges.
  • Optimal management strategies for these patients remain debated.
  • Combined or staged surgical operations are potential approaches.

Purpose of the Study:

  • To evaluate the safety and efficacy of off-pump myocardial revascularization in patients with concurrent malignancy.
  • To explore the potential impact of cardiopulmonary bypass (CPB) on malignant cell dissemination.

Main Methods:

  • Retrospective review of patients with coronary artery disease and malignancy undergoing surgical procedures.
  • Comparison of outcomes between on-pump and off-pump myocardial revascularization techniques.
  • Surgical management involved either combined procedures or staged operations for malignancy resection.

Main Results:

  • Observed potential for malignant cell dissemination during cardiopulmonary bypass in two patients.
  • Off-pump myocardial revascularization was identified as a safe approach in this patient cohort.
  • Successful application of off-pump technique in both combined and staged surgical settings.

Conclusions:

  • Off-pump myocardial revascularization is a safe and feasible strategy for patients with coronary artery disease and malignancy.
  • Avoiding cardiopulmonary bypass may mitigate the risk of malignant cell spread.
  • This technique can be integrated into both combined and staged surgical treatment plans.

More Related Videos

Cardiopulmonary Bypass in a Mouse Model: A Novel Approach08:08

Cardiopulmonary Bypass in a Mouse Model: A Novel Approach

Published on: September 22, 2017

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft05:25

Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft

Published on: September 15, 2023

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...